Abstract/Summary:

Aldosterone is an important driver of inflammation and fibrosis leading to renal and cardiovascular complications. MRA lower albuminuria but data showing prevention of end-stage kidney disease are lacking. Side effects including hyperkalemia have previously prevented long-term studies in diabetic kidney disease but new treatment strategies with potassium binders, aldosterone synthase inhibitors and nonsteroidal MRA have been developed for clinical testing.

Authors: Frimodt-Møller, Mariea; Persson, Frederika; Rossing, Petera
Keywords: diabetic kidney disease, aldosterone synthase inhibitors, nonsteroidal mineralocorticoid receptor antagonist
DOI Number: 10.1097/MNH.0000000000000557      Publication Year: 2020

To search for other research papers by topic, keyword, author, or year, please go to our Publications page.

©2021 Primary Aldosteronism Foundation — All Rights Reserved

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.

©2021 Primary Aldosteronism Foundation

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.